Fermenta Biotech LtdQ3 FY20Pharmaceuticals & Biotechnology

Fermenta Biotech Ltd

Q3 FY20 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 3

→The company expects a top-line growth at a CAGR of 15% over the next 5 years.
→Capacity utilization is currently around 80% and is expected to increase with new expansions.
→A multi-synthesis plant under construction will add ~25% capacity by Q1 FY22.
→The pharma division expects a 25% capacity increase by Q1 FY22 from ongoing CAPEX of around Rs. 30 crores.
→Demand for Vitamin D3 in the human segment is rising, both domestically and in exports; animal feed demand remains subdued due to factors like COVID impact on meat industry.
→New product launches including minerals and premix variants of D3 are planned, aligned with government fortification programs targeting edible oil and milk by FY22.
→Strategic partnerships and geographic expansions (Europe, USA) are expected to support growth without significant additional CAPEX.

Category 3

→The company expects top-line growth at a CAGR of 15% over the next 5 years.
→Bulk drug division anticipates achieving an average EBITDA margin of around 25% in the long run despite price volatility.
→Capacity expansion ongoing: Multi-synthesis plant at Dahej to increase capacity by ~25% by Q1 FY22.
→The pharma division is close to full capacity utilization, with expected 25% capacity increase by FY22 due to Rs 30 crore CAPEX.
→The company aims to sustain and improve EBITDA margins through backward integration and volume growth despite feed-grade price pressures.
→Real estate monetization is planned but delayed due to COVID-19 uncertainties.
→The company is diversifying product offerings (e.g., milk and oil fortification) with expected launches by FY22, targeting new markets.
→Overall, earnings and profitability are expected to improve gradually, supported by capacity expansions and product diversification.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Fermenta Biotech Ltd and 1,400+ other companies.

→The document does not explicitly mention any current or future plans for fundraising through debt or equity.
→The company is focusing on organic and inorganic growth opportunities with added resources post-merger.
→There is no direct reference to issuing new shares or taking on additional debt.
→Discussions reveal capital expenditure plans primarily for capacity expansion (e.g., multi-synthesis plant in Dahej with a CAPEX of around Rs 30 crores), which is expected to be funded internally.
→Monetisation of real estate assets is ongoing, possibly aimed at raising funds, but specific fundraising plans via equity or debt are not indicated.
→No mention of a public or private fundraising round in the visible sections of the report.

→The document does not provide explicit details on the current or expected order book or pending orders for the company.
→However, it mentions capacity utilization is close to 80% and above, indicating ongoing demand.
→The pharma division is near full capacity utilization, with a planned 25% capacity increase by Q1 FY22.
→Bulk drug division is dealing with market volatility, making steady-state predictions difficult.
→No specific information on pending orders or size of orderbook is stated.
→The company acknowledges increased demand for Vitamin D3 on human side but subdued demand on animal feed side due to industry slowdown.
→Supply chain improvements and logistic partnerships (e.g., in Germany) are mentioned, likely supporting order fulfillment.
→Overall, detailed order book status is not explicitly disclosed in the provided pages.

Yes

→Construction of a multi-synthesis plant in Dahej with a total CAPEX of around Rs 30 crores is underway.
→No other major CAPEX is expected in the current financial year.
→Pharma division capacity is expected to increase by 25% by Q1 FY22 due to the completion of the Rs 30 crore CAPEX.
→The Saykha project involves a planned investment of over Rs 200 crores over the next few years, to be done in a phased manner.
→Saykha project will focus on manufacturing minerals, chemical multi synthesis capabilities, and valorizing by-products like wool grease and fish oil to cholesterol.
→Commercial production at Saykha is expected to start by FY23 after environment clearance and construction.
→The company is also undertaking R&D projects, doubling R&D space, and increasing employees to support future growth.

How does Fermenta Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Fermenta Biotech Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Fermenta Biotech Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.